drugset / Trial / NCT00199238

Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria

NCT00199238

Phase 2 Terminated 248 enrolled J. Uriach and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of rupatadine for the treatment of CIU symptoms.To assess the clinical efficacy of a dose ranging of rupatadine fumarate (5mg, 10mg, and 20 mg) compared with placebo for relief of CIU symptoms.

Timeline

Start
2002-10-28
Primary completion
2003-11-25
Completion
2004-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Rupatadine Small molecule 5 mg Oral
Subject Rupatadine Small molecule 10 mg Oral
Subject Rupatadine Small molecule 20 mg Oral